DaVita (DVA) Osake Kurssi
DaVita Kurssi
Viimeisten 19 vuoden aikana DaVitan liikevaihto kasvoi 5,6 % vuodessa ja ylsi 13,64 Mrd. USD:een. Osakekohtainen tulos on kasvanut 10,0 % vuodessa viimeisten 19 vuoden aikana. DaVitan nettomarginaali 5,5 % on laskenut verrattuna 8,4 %:iin muutama vuosi sitten. DaVitan 12 kuukauden konsensustavoitehinta on 222,00 USD, noin yli kurssia 17,0 %. 13 analyytikosta 7 suosittaa ostoa — kokonaiskonsensus on Osta.
DaVita osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
DaVita liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset DaVita -osakkeesta
The main competitors of DaVita Inc in the market include companies like Fresenius Medical Care Holdings, Inc. and American Renal Associates Holdings, Inc.
DaVita Inc is a leading provider of kidney care services in the United States, offering dialysis treatments and related healthcare services. The company operates a network of outpatient dialysis centers and provides specialized medical care to patients suffering from chronic kidney failure. DaVita's business model revolves around delivering high-quality care with a patient-centric focus. By leveraging their extensive network, technological advancements, and skilled healthcare professionals, DaVita aims to improve patients' quality of life and outcomes. With a strong emphasis on innovation, collaboration, and education, DaVita Inc strives to optimize the overall healthcare experience for individuals with kidney-related conditions.
DaVita Inc is primarily active in the healthcare industry.
DaVita Inc is a leading healthcare provider that specializes in kidney care services. Established in 1999, the company has a strong history of delivering high-quality care to patients across the United States and internationally. DaVita is renowned for its innovative approaches to dialysis treatment and comprehensive disease management. The company operates a vast network of outpatient dialysis centers, partnering with physicians in providing integrated care to individuals with chronic kidney disease. With a commitment to improving patients' quality of life, DaVita remains dedicated to the compassionate delivery of kidney care services. DaVita Inc has continually expanded its footprint and leadership in the industry, making it a trusted name in renal care.
DaVita Inc. has achieved several significant milestones throughout its history. The company has expanded its presence globally, becoming one of the largest providers of kidney care services worldwide. DaVita has consistently demonstrated strong financial performance and steady growth, positioning itself as a leader in the industry. It has also received numerous accolades, including being recognized as one of Fortune's World's Most Admired Companies. DaVita Inc. continues to innovate in the field of healthcare, focusing on delivering high-quality patient care and improving outcomes.
DaVita Inc is primarily present in the United States.
DaVita Inc represents a set of core values and a strong corporate philosophy. The company focuses on delivering quality patient care, guided by their motto: "One for All and All for One." DaVita strives to provide exceptional healthcare services with integrity, teamwork, and continuous improvement. Their commitment to clinical excellence and compassion is evident in their Village concept, where employees are called "teammates" and patients are part of the DaVita community. DaVita promotes a culture of caring, innovation, and accountability, ensuring the highest standards of care for their patients.
Analyytikot asettavat tällä hetkellä DaVita-osakkeelle keskimääräisen tavoitehinnan 235,67 USD (mediaani: 222,00 USD), mikä merkitsee +24,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 13 analyytikkoarvioon.
13 analyytikkoa arvioi tällä hetkellä DaVita-osaketta: 7 suosittaa ostoa, 5 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat DaVita-yhtiöltä 14,10 Mrd. USD liikevaihtoa ja 12,77 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla DaVita-osake noteerataan hintaan 169,01 EUR (189,72 USD).
DaVita-osake (DVA) on listattuna 7 pörssissä, muun muassa: NYSE (DVA), London (0I7E.L), SIX (Zürich) (TRL.SW), Frankfurt (TRL.F), München (TRL.MU), Düsseldorf (TRL.DU).
The business model of DaVita Inc is focused on the healthcare and medical services sector. The company's main focus is on treating patients with chronic kidney diseases. DaVita has developed a comprehensive integrated healthcare solution that includes multiple services. These include renal replacement therapy, care, education, and medical treatment. In recent years, the company has also added expanded services such as nutritional counseling, mental health, and rehabilitation to its portfolio. To provide the necessary medical care and healthcare services, DaVita operates around 2,700 dialysis centers with over 200,000 facilities worldwide. The company also employs over 70,000 staff, including physicians, nursing staff, therapists, and administrative personnel. DaVita offers a wide range of products and services, including hemodialysis, peritoneal dialysis, and home patient equipment. The company also offers various programs to improve patient care quality and increase patient engagement. These programs include global quality and safety initiatives, patient surveys, and electronic medical records. DaVita has also established its own health insurance called DaVita Health Plan, which offers a wide range of health plans in the United States. The company also operates a comprehensive marketing program to raise awareness of its services among patients and physicians. To drive growth in different markets, DaVita seeks to offer the best possible healthcare services through strategic acquisitions and joint ventures. In recent years, the company has announced several acquisitions and partnerships to expand its geographic reach and service offerings. In recent years, the company has been following a trend towards digital innovations. DaVita has transitioned its originally paper-based processes to digital platforms to improve care quality, patient experience, and efficiency. The company also utilizes the latest technologies to offer innovative and personalized services to its patients and improve patient experiences. In summary, DaVita Inc is a leading company in the field of kidney diseases and offers a wide range of healthcare services and products. The company has a strong presence in the United States and operates in various geographical regions worldwide. DaVita has evolved its services over the years and developed an extensive portfolio of products and services, including health insurance, digital platforms, and innovative therapies.
odotettu liikevaihto DaVita on 14,10 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto DaVita on 1,13 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
DaVita:n hinta-voitto-suhde (P/E) on tällä hetkellä 14,86. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan DaVita-osakkeen arvostusta.
DaVita:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,19. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii DaVita-osakkeen arvostuskennuslukuna.
DaVita:n Eulpool-laatuscore on 6/10.
DaVita:n ISIN on US23918K1088. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
DaVita:n WKN on 897914. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
DaVita:n ticker on DVA. Tämä pörssinoteeraus käytetään DaVita-osakkeiden kauppaan pörssissä.
DaVita osake
DaVita vertaisryhmä
DaVita Ticker
DaVita FIGI
Kaikki tunnusluvut ja syvällinen analyysi DaVita:sta
Meidän osakeanalyysimme DaVita-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut DaVita:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: